Research Analysts’ Weekly Ratings Updates for Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics (NASDAQ: IKT) has recently received a number of price target changes and ratings updates:

• 7/31/2026 – Inhibikase Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.
• 7/26/2026 – Inhibikase Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/18/2026 – Inhibikase Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/17/2026 – Inhibikase Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Inhibikase Therapeutics was upgraded by LADENBURG THALM/SH SH to “strong-buy”.
• 6/10/2026 – Inhibikase Therapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $5.00 price target on the stock.

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.